APPROVED – CSU IBC Meeting Minutes

Meeting title	CSU IBC Meeting October 2025
Date	October 15, 2025
Convened at	2:32PM MST
Location	Microsoft Teams (Virtual Meeting)
Open or closed meeting (If closed, why?)	The meeting was closed briefly from 3:20pm to 3:35pm to discuss personal, proprietary, and/or security matters. The meeting was open the remainder of the time.
Review of prior meeting minutes	August 13, 2025 and September 10, 2025 minutes were approved as written
Adjournment	3:27 PM MST
Recorded by	M. Ramey & C. Johnson

Attendees

Check if Attending (Members):	**Check if Attending (Alternate Members):**
☒ Jessica Ayers, Animal expert	☐ Lon Kendall, Director LAR
☐ Donald Bade, Unaffiliated	
☒ Angela Bosco-Lauth, Veterinary Virology	
☒ Chaoping Chen, Chair	
☒ Jason Cummings, lab representative	
☒ Dan Frazen, Unaffiliated	
☐ Jean Peccoud, Synthetic Biology	
☒ Brendan Podell, Mycobacteria specialist	
☐ Ann Powers, Virology	
☐ Robyn Roberts, Plant expert	
☒ Joanie Ryan, Assistant Biosafety Director	☒ Rebecca Moritz, Biosafety Office Director*
☐ Tony Schountz, Virology	☒ Christine Johnson, IBC/IRE Manager, Alternate-at-Large*
Quorum = 7 voting members; 7 in attendance	*non-voting at this meeting
Non-Voting Members:	
☒ James Graham, EHS Director	
☐ Joni Van Sickle, Occupational Health Coord.	
ORCC Staff (non-voting):	
☒ Michelle Ramey, Assistant Compliance Coord.	☐ Sonia Aleman Rivera, Assistant Biosafety Officer
☒ Nicole Marlenee, Biosecurity Specialist	☒ Kelly Kim, Assistant Biosafety Officer
☒ Scott Van Scotter, Biosafety Trainer	
Additional Guests:	
Mario Arango, OGC and Jim Abraham, EHS	

Quorum was maintained throughout. Any member with a conflict of interest left the meeting during discussion and/or committee determination on the conflicted items.

1. Agent/Project Review

a. PI name/Lab	Cawley Lab
Project Number and Title	**25-062B: Understanding hemangiosarcoma angiogenesis**
Agents used	• *LentiX*
Project Overview	This project involves evaluating the role of angiogenic plasticity in hemangisoarcoma progression.
Planned Modifications	Cancer and control cell lines will be transduced with an inducible cas9 construct, and then CRISPR screen against top transcription factor targets will be performed in vitro. Follow up validation will be performed using shRNA or CRISPR edited cells in vitro and in vivo.
NIH Guidelines Section	III-D-1, III-D-3, III-D-4
Proposed containment conditions (BSL, ABSL, etc.)	BSL2/ABSL2
Discussion	This is a newly established lab: 1. HEK293T cells are mentioned in the Viral Vector Form, but not in the Source Materials. Please clarify. 2. Angiosarcoma from humans should be changed to BSL-2 3. It was noted that 100% ethanol is indicated. 70% ethanol is more effective and should be used instead of 100% for cleaning surfaces. 4. If other lab members will participate in this work, they need to be added to the Project 5. Under Rooms and Spaces, please identify the animal rooms used. For the agent 6. Under methods of disinfection, the form indicates the use of 10% bleach followed by autoclaving. Please note, 10% is sufficient for lentivirus disinfection. If the Lab wants to autoclave materials after bleaching, the items should set overnight to avoid damage to the autoclave.
Verification of training	Training requirements need to be completed.
Verification of facilities	New Lab, a biosafety visit is required.
Motion	A motion was made to approve the project pending modifications described above (see Discussion).
Vote	The motion was unanimously approved.

b. PI name/Lab	Braunstein Lab
Project Number and Title	**25-063B: Transposon mutagenesis in the NTM Mycobacterium abscessus**
Agents used	• *Mycobacterium abscessus; strain- ATCC 19977*
Project Overview	One of the intrinsic drug resistance mechanisms of Mycobacterium abscessus is its highly impermeable cell wall, which poses a challenge for drug entry into the bacteria. This project aims to conduct a transposon mutagenesis project to discover transposon insertion mutants that impart increased cell

	wall permeability. The goal of this project is to understand the challenges posed by the cell wall of M. abscessus to drug treatment, which will enable rational strategies to overcome this barrier.
Planned Modifications	N/A
NIH Guidelines Section	N/A
Proposed containment conditions (BSL, ABSL, etc.)	BSL2
Discussion	This is an experienced PI in MIP 1. Remind the PI to add personnel once the project starts
Verification of training	All lab personnel training is current.
Verification of facilities	The lab is up to date on lab inspections.
Motion	A motion was made to approve the project as written.
Vote	The motion was unanimously approved.

c. PI name/Lab	**Henao-Tamayo Lab**
Project Number and Title	**19-099B: Vaccine Induced Immunity to tuberculosis - Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAC-TB)**
Agents used	• *Mycobacterium avium Complex (MAC)* • *Mycobacterium bovis BCG* • *Mycobacterium tuberculosis; Strain- HN878* • *Mycobacterium tuberculosis; Strain- H37Rv* • *Mycobacterium tuberculosis; Strain- Erdman* • *Mycobacterium tuberculosis*
Project Overview	This project will investigate immune response in the context of tuberculosis. To accomplish this, they will 1) look at the impact of BCG vaccination, alternative vaccine candidates, and vaccination-boosting strategies on the kinetics and longevity of the immune response. 2) examine the impact of clinical Mtb strains on humoral and cellular immunity induction in both naive and vaccinated animals and 3) determine the impact of environmental mycobacteria exposure on these vaccination strategies.
Planned Modifications	N/A
NIH Guidelines Section	N/A
Proposed containment conditions (BSL, ABSL, etc.)	BSL3/ABSL3
Project Number and Title	**20-040B: COVID-19 vaccine | Rapid Response Technical/Operations/Research Teams (RAPTORs)**
Agents used	• SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)

Project Overview	The goal of this project to elucidate the immune phenotype elicited by SARS-CoV-2 as well as what inductive effects the potential vaccine/adjuvant produces in these animals. The lab will receive samples from hamsters that have been vaccinated with PBS, adjuvant, vaccine, or vaccine adjuvant, and then challenged with SARS-CoV-2. They will process lungs and spleens and isolate PBMC for blood for flow cytometry and 10x sequencing.
Planned Modifications	N/A
NIH Guidelines Section	N/A
Proposed containment conditions (BSL, ABSL, etc.)	BSL3
Project Number and Title	**21-050B: Evaluation of MPL compounds and Oxazolidinones against M. abscessus in a SCID mouse infection model**
Agents used	• *Mycobacterium abscessus* • *Mycobacterium Avium Complex*
Project Overview	The purpose of this project is to evaluate in-vivo activity of MPL and oxazolidinones against Mycobacterium abscessus. The lead MPL and oxazolidinones will be used in acute SCID (Severe combined immunodeficiency) mouse models infected with Mycobacterium abscessus to measure the ability of the compound to reduce the bacterial growth, penetrate granulomas, improve organ pathology, and overall disease outcome.
Planned Modifications	N/A
NIH Guidelines Section	N/A
Proposed containment conditions (BSL, ABSL, etc.)	BSL3/ABSL3
Project Number and Title	**25-019B: Research Diabetes (25-019B); BSL2 Training Program in Metabolism**
Agents used	• *Mycobacterium vaccae; Strain- ATCC 15483*
Project Overview	The overall objective for this project is to investigate whether treating drinking water with non-tuberculosis mycobacteria (NTM) can prevent Western-Diet induced weight gain in male mice. To accomplish our goal, we will assess weekly weights, visceral adipose tissue weights, and immunoregulatory markers.
Planned Modifications	N/A
NIH Guidelines Section	N/A
Proposed containment conditions (BSL, ABSL, etc.)	BSL3/ABSL3
Discussion	This is an experienced PI in MIP. All projects have been previously approved, and were modified when migrating the information to SciShield, thus requiring them to be re-reviewed.

	For #20-040B: Please clarify whether any of this work is occurring at BSL-2. If so, specify the strains of SARS-CoV-2 used, and the tasks being performed. For #21-050B: 1. Please remove the "Questions" from the project summary. 2. Please update the locations of work and correct the appropriate section. 3. Please confirm the route of in vivo infections. For #25-019B: 1. Please clarify whether a surgical mask is needed for in vivo work. 2. Specify room numbers for ABSL2 work in the text and update the associated rooms. For #19-099B: Please correct the vesphene dilution; the highest dilution should be 1:128.
Verification of training	All lab personnel training is current.
Verification of facilities	The lab is up to date on lab inspections.
Motion	A motion was made to approve the project pending modifications described above (see Discussion).
Vote	The motion was unanimously approved.

d. PI name/Lab	**Dean Lab**
Project Number and Title	**25-069B: Novel Recombinant African Swine Fever Vaccine Using Probiotic Organism Lactobacillus Acidophilus**
Agents used	• *Lactobacillus acidophilus; Strain- Recombinant Wild Type* • *Lactobacillus spp; any*
Project Overview	This work seeks to develop a novel, African Swine Fever Virus (ASFV) vaccine for the prevention of ASF using the bacterium recombinant Lactobacillus acidophilus (rLA) as an orally delivered vaccine platform for a variety of viral antigens. rLA will express ASFV protein. No live virus will be used in any part of this study.
Planned Modifications	The ASF protein inserted into rLA is a portion of the p72 ASF protein, sequence from GenBank; we will test the efficacy of our novel rLA ASF vaccine in a murine system.
NIH Guidelines Section	III-D-2/III-D-4
Proposed containment conditions (BSL, ABSL, etc.)	BSL2/ABSL2
Discussion	This is an experienced PI who has done similar work 1. Please briefly describe how the lab is going to generate the recombinant vaccine. 2. Will you be sourcing just the proteins for ASF from a commercial source or receiving an attenuated virus? What strain of ASF will be used?

	3. Please associate the appropriate Source Materials to the new project and add any Source Materials if needed.
Verification of training	Training requirements need to be completed.
Verification of facilities	Biosafety visit up to date.
Motion	A motion was made to approve the project pending modifications described above (see Discussion).
Vote	The motion was unanimously approved.

2. Amendments requiring full IBC review

a. PI name/Lab	**Sloan Lab**
Project Number and Title	**20-124B: Modification of Arabidopsis organelle DNA polymerase fidelity**
Agents used	• *Agrobacterium tumefaciens; Strain-GV3101*
Project Overview	Plant mitochondrial and chloroplast genomes have unusually low mutation rates. The planned research will test hypotheses about the role of DNA polymerase fidelity in maintaining these low mutation rates by engineering a modified version of the Arabidopsis PolIb polymerase that lacks a functional exonuclease proofreading domain
Amendment request	We would like to amend this PARF to include additional target genes to address how the fidelity of Arabidopsis DNA polymerases interacts with DNA repair factors and additional host. There would be no changes to the agent (Agrobacterium).
Planned Modifications	Site directed mutagenesis will be used to replace key amino acids in the exonuclease domain. The gene encoding this modified polymerase will be transformed in to Arabidopsis by the Agrobacterium floral dip method. Effects on mitochondrial and chloroplast mutation rates will be assessed by deep sequencing.
NIH Guidelines Section	III-E-2
Proposed containment conditions (BSL, ABSL, etc.)	BSL1/BSL-P
Discussion	This is an experienced PI from BMS The IBC requests the statement regarding Goggles being available but only used when needed, be corrected to reflect the eye-protection policy which requires eye protection to be worn in the lab at all times.
Verification of training	All lab members are up to date on the required training.
Verification of facilities	The is up to date on lab inspections.
Motion	A motion was made to approve the amendment request pending modifications described above (see Discussion)
Vote	The motion was unanimously approved.

3. **New Business**
    a. **NIH Launches Comprehensive Effort to Modernize Biosafety Framework** (https://www.nih.gov/about-nih/nih-director/statements/nih-launches-initiative-modernize-strengthen-biosafety-oversight)
    The IBC Manager gave an overview of the NIH initiative and discussed the slides shared at the first listening session. There will be some time before the listening session in our region will be scheduled. The IBC Manager encouraged the committee to think about any comments/questions they might have prior to our listening session.

4. **Unfinished Business**
    a. **SciShield Migration – ongoing**
    b. **McKay Lab – TABLED from September meeting, still awaiting response**
        i. **Pathogen Registration Forms**
            1. Bacteria - Xanthomonas vasicola vasculorum
        ii. **Project -** Identification of Durable Disease Tolerance Gene(s) under Drought Stress in Maize (25-059B); BSL1/BSL1-P. NIH Guidelines category non-exempt rDNA: NA

5. **Reports**

a. Coordinator's Report	Next IBC meeting: Wednesday, November 12, 2025
b. Biosafety Office Report	1. Inspections update: The biosafety team are in the process of closing out the select agent inspection from this spring. 2. Incident Reports: There were no incidents involving recombinant materials during the past quarter. 3. Biosafety Outreach Visits: The biosafety team has been conducting a lot visits to labs.

6. **Items to be read into the minutes**

1. Items Reviewed at Previous IBC Meeting and Approved After Modification were completed	**1. VandeWoude, Sue** **a. Agent:** Avian Influenza, Influenza A – Strain: any/unknown; BSL2 b. **Project:** Emerging infectious disease research of zoonotic potential, genomic surveillance of avian influenza viruses in select mammalian species (23-053B); BSL2. NIH Guidelines category non-exempt rDNA: NA **2. Bowen, Richard** a. **Project:** Immunization of chickens against avian influenza using a helper-independent adenovirus vector (25-057B); BSL3/ABSL3, rDNA. NIH Guidelines category non-exempt rDNA: III-D-1/III-D-4 **3. Tsunoda, Susan** a. **Project:** Regulation of ion channels and synaptic activity (16-066B); BSL1, rDNA. NIH Guidelines category non-exempt rDNA: III-D-4

	Project amended to add Drosophila melanogaster **4. Kading Lab** **a. Project -** Arbovirus surveillance of mosquitoes from Myanmar (25-060B); BSL3. NIH Guidelines category non-exempt rDNA: NA **5. Schountz, Tony** **a. Project -** Jeilongvirus infection of deer mice (25-002B); BSL2/ABSL2. NIH Guidelines category non-exempt rDNA: NA
6. Items Reviewed and Approved by the Biosafety Officer or Chair since the last meeting	**1. Chan, Joshua** a. **Project:** Engineering and culturing Lactococcus lactis communities (25-043B); BSL1, exempt rDNA. NIH Guidelines category non-exempt rDNA: III-F-8 **2. Bell, Christopher** a. **Project:** Use of Neuromuscular Electrical Stimulation to Prevent Exercise Resistance, A Pilot Study (25-054B); BSL2, human samples. NIH Guidelines category non-exempt rDNA: NA